Recently, Hangzhou Tangji Medical Technology Co., Ltd. received exciting news as the National Medical Products Administration approved the registration application for its innovative product, the "Gastric Bypass Stent System." This marks a significant milestone as it is the first certificate obtained by a Chinese company for weight loss devices globally, based on this principle.

Preclinical animal trials for this product were successfully conducted at East Point Medical. East Point Medical's technical team played a crucial role in implementing standardized SOP processes, including literature review, plan design, animal ethics approval, conducting animal experiments, postoperative care, analysis of pathological results, and submission of the final preclinical evaluation report. This ensured the standardization of the experimental process, authenticity of data, and reliability of results. Post-launch, East Point Medical plans to collaborate with customers to provide clinical medical training and accelerate clinical promotion after product certification.

The Gastric Bypass Stent System developed by Tangji Medical is inspired by the principles of the most effective gastric bypass surgery (RYGB) in weight loss surgery. Through minimally invasive intervention, a cannula is placed in the duodenum and upper jejunum to isolate chyme, reducing its contact with the intestinal wall and absorption of sugar and fat. Additionally, by isolating food stimulation on the small intestine through a scaffold, it reshapes intestinal morphology and mucosal structure, promoting faster turnover of gastrointestinal cells. Furthermore, it directs insufficiently digested food to the distal end of the jejunum, stimulating GLP-1 receptor secretion in the jejunum and ileum, thereby promoting hypoglycemia and weight loss. Additionally, stent placement fundamentally improves human gut microbiota, increasing the proportion of probiotics significantly.

In the future, EastPoint Innovation remains committed to its core values of fairness, professionalism, innovation, and efficiency, providing continuous support for global innovation and development in medical devices.